EP0179808A4 - Pharmaceutical composition suitable for treatment or prophylaxis of cardiac disorders. - Google Patents
Pharmaceutical composition suitable for treatment or prophylaxis of cardiac disorders.Info
- Publication number
- EP0179808A4 EP0179808A4 EP19850901817 EP85901817A EP0179808A4 EP 0179808 A4 EP0179808 A4 EP 0179808A4 EP 19850901817 EP19850901817 EP 19850901817 EP 85901817 A EP85901817 A EP 85901817A EP 0179808 A4 EP0179808 A4 EP 0179808A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- prophylaxis
- treatment
- pharmaceutical composition
- composition suitable
- cardiac disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L65/00—Network arrangements, protocols or services for supporting real-time applications in data packet communication
- H04L65/1066—Session management
- H04L65/1083—In-session procedures
- H04L65/1095—Inter-network session transfer or sharing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Multimedia (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Cardiology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Signal Processing (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59806184A | 1984-04-09 | 1984-04-09 | |
US598061 | 2000-06-20 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0179808A1 EP0179808A1 (en) | 1986-05-07 |
EP0179808A4 true EP0179808A4 (en) | 1987-10-27 |
EP0179808B1 EP0179808B1 (en) | 1991-10-30 |
Family
ID=24394068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP85901817A Expired - Lifetime EP0179808B1 (en) | 1984-04-09 | 1985-03-25 | Pharmaceutical composition suitable for treatment or prophylaxis of cardiac disorders |
Country Status (9)
Country | Link |
---|---|
US (1) | US5017609A (en) |
EP (1) | EP0179808B1 (en) |
JP (1) | JPH0720861B2 (en) |
AU (1) | AU575153B2 (en) |
CA (1) | CA1242395A (en) |
DE (1) | DE3584560D1 (en) |
IT (1) | IT1184271B (en) |
WO (1) | WO1985004580A1 (en) |
ZA (1) | ZA852316B (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4857552A (en) * | 1988-06-08 | 1989-08-15 | E. I. Du Pont De Nemours And Co. | Stable pharmaceutical composition |
GR1000509B (en) * | 1988-06-08 | 1992-07-30 | Du Pont | A method of making a stable injectable aqueous composition of methyl3-[4-(2-hydroxy-3-isopropylamino) propoxy] phenylproprionate hydrochloride |
US6310094B1 (en) * | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
AU2002337692B2 (en) * | 2001-09-26 | 2007-09-13 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
UA89781C2 (en) * | 2004-04-07 | 2010-03-10 | Арес Трейдінг С.А. | Liquid growth hormone formulation |
WO2006010630A1 (en) * | 2004-07-30 | 2006-02-02 | Novartis Ag | Compound formulations of 2-amino-1, 3-propanediol compounds |
WO2006138202A2 (en) * | 2005-06-14 | 2006-12-28 | Baxter International Inc. | Pharmaceutical formulations for minimizing drug-drug interactions |
US20070134341A1 (en) * | 2005-11-15 | 2007-06-14 | Kipp James E | Compositions of lipoxygenase inhibitors |
WO2008080047A2 (en) * | 2006-12-23 | 2008-07-03 | Baxter International Inc. | Magnetic separation of fine particles from compositions |
AU2014203121B2 (en) * | 2007-05-22 | 2016-04-21 | Baxter Healthcare Sa | Concentrate esmolol |
US8426467B2 (en) * | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
US8722736B2 (en) * | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
US20080293814A1 (en) * | 2007-05-22 | 2008-11-27 | Deepak Tiwari | Concentrate esmolol |
AU2008340179B2 (en) | 2007-12-21 | 2014-10-23 | Aop Orphan Pharmaceuticals Gmbh | Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists |
ES2443159T3 (en) | 2009-09-22 | 2014-02-18 | Vlife Sciences Technologies Pvt Ltd. | Topical formulation for diabetic foot ulcers |
WO2012103314A1 (en) | 2011-01-27 | 2012-08-02 | Baxter International Inc. | Methods of treating tachycardia and/or controlling heart rate while minimizing and/or controlling hypotension |
MX2013008715A (en) | 2011-01-27 | 2013-08-29 | Baxter Healthcare Sa | Use of (s) - esmolol for controlling venous irritation associated with the treatment of a cardiac disorder. |
CN104473869A (en) * | 2014-11-20 | 2015-04-01 | 北京京科泰来科技有限公司 | Esmolol fat emulsion and preparation method thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3637852A (en) * | 1963-08-26 | 1972-01-25 | Boehringer Sohn Ingelheim | 1-phenoxy-2-hydroxy-3-isopropylamino-propanes and salts thereof |
DE1643262C3 (en) * | 1967-12-13 | 1975-06-26 | C.H. Boehringer Sohn, 6507 Ingelheim | i-Phenoxy ^ -hydroxy-S-alklyaminopropane, process for their preparation and medicaments containing these compounds |
US4191765A (en) * | 1976-05-25 | 1980-03-04 | Hoechst Aktiengesellschaft | 1-Aryloxy-2-hydroxy-3-aminopropanes |
US4146630A (en) * | 1976-11-12 | 1979-03-27 | Boehringer Mannheim Gmbh | Blood pressure lowering and adrenergic β-receptor inhibiting 3-(4-phenoxymethylpiperidino)-propyl-phenyl ethers |
DE2905877A1 (en) * | 1979-02-16 | 1980-08-28 | Boehringer Mannheim Gmbh | NEW AMINOPROPANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
DE3015991A1 (en) * | 1980-04-25 | 1981-11-05 | C.H. Boehringer Sohn, 6507 Ingelheim | NEW 1-ARYLOXY-3-ALKYLAMINO-2-PROPANOLS AND METHOD FOR THE PRODUCTION THEREOF |
SE8004087L (en) * | 1980-06-02 | 1981-12-03 | Haessle Ab | NEW PARA-SUBSTITUTED 3-PHENOXY-1-ALKYLAMINOPROPANOL-2 WITH BETARETTY RECEPTOR BLOCKING PROPERTIES, AND PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME, AND METHOD OF ACCOUNTING ... |
US4387103A (en) * | 1980-11-28 | 1983-06-07 | American Hospital Supply Corporation | Method for treatment or prophylaxis of cardiac disorders |
US4829086A (en) * | 1984-03-14 | 1989-05-09 | Bodor Nicholas S | Soft β-adrenergic blocking agents |
-
1985
- 1985-03-25 AU AU41507/85A patent/AU575153B2/en not_active Ceased
- 1985-03-25 JP JP60501518A patent/JPH0720861B2/en not_active Expired - Fee Related
- 1985-03-25 DE DE8585901817T patent/DE3584560D1/en not_active Expired - Lifetime
- 1985-03-25 WO PCT/US1985/000492 patent/WO1985004580A1/en active IP Right Grant
- 1985-03-25 EP EP85901817A patent/EP0179808B1/en not_active Expired - Lifetime
- 1985-03-27 ZA ZA852316A patent/ZA852316B/en unknown
- 1985-03-29 CA CA000477920A patent/CA1242395A/en not_active Expired
- 1985-04-05 IT IT47927/85A patent/IT1184271B/en active
-
1989
- 1989-11-16 US US07/437,293 patent/US5017609A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE3584560D1 (en) | 1991-12-05 |
JPS61501775A (en) | 1986-08-21 |
IT1184271B (en) | 1987-10-22 |
WO1985004580A1 (en) | 1985-10-24 |
CA1242395A (en) | 1988-09-27 |
EP0179808A1 (en) | 1986-05-07 |
ZA852316B (en) | 1985-11-27 |
EP0179808B1 (en) | 1991-10-30 |
JPH0720861B2 (en) | 1995-03-08 |
AU4150785A (en) | 1985-11-01 |
US5017609A (en) | 1991-05-21 |
IT8547927A0 (en) | 1985-04-05 |
AU575153B2 (en) | 1988-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2188844B (en) | Pharmaceutical composition for the treatment of psoriasis | |
IL83925A0 (en) | Compositions for treatment of skin disorders | |
GB2206788B (en) | 5 ht-3 antagonist for the treatment or reduction of dependence | |
EP0179808A4 (en) | Pharmaceutical composition suitable for treatment or prophylaxis of cardiac disorders. | |
IL76591A (en) | Pharmaceutical compositions containing ifn-ypsilon for the treatment or prevention of malignant or viral diseases | |
EP0243002A3 (en) | Pharmaceutical composition for the treatment of periodontal diseases | |
EP0065542A4 (en) | Compounds suitable for treatment or prophylaxis of cardiac disorders. | |
GB8420771D0 (en) | Treatment of skin disorders | |
ZA857081B (en) | Composition for the treatment of allergy | |
IL76561A (en) | Pharmaceutical compositions containing ifn-ypsilon for the treatment of rheumatic diseases | |
EP0065964A4 (en) | Method for treatment or prophylaxis of cardiac disorders. | |
AU7896781A (en) | Method for treatment or prophylaxis of cardiac disorders | |
GB8810422D0 (en) | Ophthalmological composition of matter | |
DE3261760D1 (en) | Pharmaceutical compositions for the treatment of skin | |
DE3460620D1 (en) | Pharmaceutical or veterinary composition for the treatment of ischemic cardiac disorders | |
GB2204488B (en) | Pharmaceutical compositions for the treatment or prophylaxis of skin disorders | |
GB2162748B (en) | Medicinal composition for the treatment or prevention of acne by oral administration | |
GB2165453B (en) | Pharmaceutical agent for the local treatment of psoriasis | |
AU591107B2 (en) | Psoralene-based bath compositions for treatment of skin disorders | |
GB8715914D0 (en) | Treatment of cerabral disorders | |
EP0078533A3 (en) | Medicinal composition for treating skin disorders | |
GR3000306T3 (en) | Composition for the treatment of infections | |
EP0344820A3 (en) | Means for the treatment of cardiac diseases | |
EP0190219A4 (en) | Composition for the treatment of haemorrhoids. | |
IL82376A (en) | Pharmaceutical composition for the treatment of inflammatory conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19860221 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): CH DE FR GB LI SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19871027 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: E.I. DU PONT DE NEMOURS AND COMPANY |
|
17Q | First examination report despatched |
Effective date: 19890413 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): CH DE FR GB LI SE |
|
REF | Corresponds to: |
Ref document number: 3584560 Country of ref document: DE Date of ref document: 19911205 |
|
ET | Fr: translation filed | ||
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: THE DU PONT MERCK PHARMACEUTICAL COMPANY |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Free format text: THE DU PONT MERCK PHARMACEUTICAL COMPANY |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: OHMEDA (FORMERLY KNOWN AS BOC HEALTH CARE) |
|
EAL | Se: european patent in force in sweden |
Ref document number: 85901817.8 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: BECTON DICKINSON INFUSION THERAPY UK TRANSFER- BAX Ref country code: CH Ref legal event code: PFA Free format text: OHMEDA (FORMERLY KNOWN AS BOC HEALTH CARE) TRANSFER- BECTON DICKINSON INFUSION THERAPY UK Ref country code: CH Ref legal event code: NV Representative=s name: ISLER & PEDRAZZINI AG |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20040317 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20040318 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20040319 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20040322 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20040430 Year of fee payment: 20 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20050324 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20050324 Ref country code: CH Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20050324 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
EUG | Se: european patent has lapsed |